Metraipolis › archive › dc_2201e3670ec3

Transcriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus — Europe PMC PMID:37616377

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/37616377
DOI
10.1080/22221751.2023.2252513
License (as archived)
CC0-1.0
Archived
2026-10-07T11:30:50.375Z
SHA-256 of the archived text
d33fea6bf9f78aee6af1830a3feee83aa550600acf2ab0a08dd1eb07c1295f63
Stable URL of this page
https://metraipolis.com/documento/dc_2201e3670ec3

How to cite

Transcriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus — Europe PMC PMID:37616377 — Europe PMC (en), https://europepmc.org/article/MED/37616377 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_2201e3670ec3 (Metraipolis archive dc_2201e3670ec3, sha256 d33fea6bf9f78aee6af1830a3feee83aa550600acf2ab0a08dd1eb07c1295f63)
BibTeX
@misc{dc2201e3670ec3,
  title = {Transcriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus — Europe PMC PMID:37616377},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/37616377},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_2201e3670ec3; sha256 d33fea6bf9f78aee6af1830a3feee83aa550600acf2ab0a08dd1eb07c1295f63},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37616377. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Infection with Marburg virus (MARV), the causative agent of Marburg virus disease (MVD), results in haemorrhagic disease and high case fatality rates (>40%) in humans. Despite its public health relevance, there are no licensed vaccines or therapeutics to prevent or treat MVD. A vesicular stomatitis virus (VSV)-based vaccine expressing the MARV glycoprotein (VSV-MARV) is currently in clinical development. Previously, a single 10 million PFU dose of VSV-MARV administered 1-5 weeks before lethal MARV challenge conferred uniform protection in nonhuman primates (NHPs), demonstrating fast-acting potential. Additionally, our group recently demonstrated that even a low dose VSV-MARV (1000 PFU) protected NHPs when given 7 days before MARV challenge. In this study, we longitudinally profiled the transcriptional responses of NHPs vaccinated with this low dose of VSV-MARV either 14 or 7 days before lethal MARV challenge. NHPs vaccinated 14 days before challenge presented with transcriptional changes consistent with an antiviral response before challenge. Limited gene expression changes were observed in the group vaccinated 7 days before challenge. After challenge, genes related to lymphocyte-mediated immunity were only observed in the group vaccinated 14 days before challenge, indicating that the length of time between vaccination and challenge influenced gene expression. Our results indicate that a low dose VSV-MARV elicits distinct immune responses that correlate with protection against MVD. A low dose of VSV-MARV should be evaluated in clinical rails as it may be an option to deliver beneficial public health outcomes to more people in the event of future outbreaks.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: Emerging microbes & infections, 2023 (prima pubblicazione 2023-12-01).
Identificativi: PMID 37616377 · PMCID PMC10498809 · DOI 10.1080/22221751.2023.2252513.
Parole chiave degli autori: Vesicular stomatitis virus; Filovirus; Nonhuman Primate; Host Response; Marv; Marburg Virus Angola.
Descrittori MeSH principali: Marburg Virus Disease; Marburgvirus.
Pagina: https://europepmc.org/article/MED/37616377 — https://doi.org/10.1080/22221751.2023.2252513. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-07T11:17:31.030Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.